| Dr Jeffrey M Weber, MD | |
|
2901 W. Kk River Pkwy., Suite 414, Milwaukee, WI 53215-3660 | |
| (414) 649-3750 | |
| (414) 649-3411 |
| Full Name | Dr Jeffrey M Weber |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 50 Years |
| Location | 2901 W. Kk River Pkwy., Milwaukee, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962465047 | NPI | - | NPPES |
| 30249200 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 21101 (Wisconsin) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Infuseable Healthcare, Llc | 8921418013 | 4 |
News Archive
Tantalizing treasures of neural knowledge that lie deep in the brain of the common fruit fly are one step closer to being laid bare, now that a team of six Stanford researchers has been awarded a $1.3 million medical research grant by the W. M. Keck Foundation.
Nearly two million babies are stillborn every year, with 84 per cent of cases occurring in low- and lower middle-income countries, says an 8 October report by WHO, UNICEF and partners.
Sermo, the world's largest online community for physicians, today announced a Sermo Event Report titled "Is there any Threat to Anti-TNFs from Newer Biologic DMARDs?" In the past year, the FDA has approved four new biologic DMARDs – Actemra (Genentech), Orencia (Bristol-Myers Squibb), Simponi (Centocor Ortho Biotech), and Cimzia (UCB). According to the report, Orencia leads the pack among physicians as the next line of treatment for patients who fail two or more TNF antagonists.
Confluent Surgical, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the DuraSeal Dural Sealant System as the first and only product indicated as an adjunct to sutured dural repair during cranial surgery to achieve watertight closure. The FDA has approved the DuraSeal Sealant with a condition to conduct a post-approval study.
Cancer patients with annual household incomes below $50,000 were less likely to participate in clinical trials than patients with annual incomes of $50,000 or higher, and were more likely to be concerned about how to pay for clinical trial participation.
› Verified 3 days ago
| Entity Name | Ctca Physicians Group Of Arizona Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609026806 PECOS PAC ID: 2264593474 Enrollment ID: O20081205000793 |
News Archive
Tantalizing treasures of neural knowledge that lie deep in the brain of the common fruit fly are one step closer to being laid bare, now that a team of six Stanford researchers has been awarded a $1.3 million medical research grant by the W. M. Keck Foundation.
Nearly two million babies are stillborn every year, with 84 per cent of cases occurring in low- and lower middle-income countries, says an 8 October report by WHO, UNICEF and partners.
Sermo, the world's largest online community for physicians, today announced a Sermo Event Report titled "Is there any Threat to Anti-TNFs from Newer Biologic DMARDs?" In the past year, the FDA has approved four new biologic DMARDs – Actemra (Genentech), Orencia (Bristol-Myers Squibb), Simponi (Centocor Ortho Biotech), and Cimzia (UCB). According to the report, Orencia leads the pack among physicians as the next line of treatment for patients who fail two or more TNF antagonists.
Confluent Surgical, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the DuraSeal Dural Sealant System as the first and only product indicated as an adjunct to sutured dural repair during cranial surgery to achieve watertight closure. The FDA has approved the DuraSeal Sealant with a condition to conduct a post-approval study.
Cancer patients with annual household incomes below $50,000 were less likely to participate in clinical trials than patients with annual incomes of $50,000 or higher, and were more likely to be concerned about how to pay for clinical trial participation.
› Verified 3 days ago
| Entity Name | Infuseable Healthcare, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689288938 PECOS PAC ID: 8921418013 Enrollment ID: O20201030001199 |
News Archive
Tantalizing treasures of neural knowledge that lie deep in the brain of the common fruit fly are one step closer to being laid bare, now that a team of six Stanford researchers has been awarded a $1.3 million medical research grant by the W. M. Keck Foundation.
Nearly two million babies are stillborn every year, with 84 per cent of cases occurring in low- and lower middle-income countries, says an 8 October report by WHO, UNICEF and partners.
Sermo, the world's largest online community for physicians, today announced a Sermo Event Report titled "Is there any Threat to Anti-TNFs from Newer Biologic DMARDs?" In the past year, the FDA has approved four new biologic DMARDs – Actemra (Genentech), Orencia (Bristol-Myers Squibb), Simponi (Centocor Ortho Biotech), and Cimzia (UCB). According to the report, Orencia leads the pack among physicians as the next line of treatment for patients who fail two or more TNF antagonists.
Confluent Surgical, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the DuraSeal Dural Sealant System as the first and only product indicated as an adjunct to sutured dural repair during cranial surgery to achieve watertight closure. The FDA has approved the DuraSeal Sealant with a condition to conduct a post-approval study.
Cancer patients with annual household incomes below $50,000 were less likely to participate in clinical trials than patients with annual incomes of $50,000 or higher, and were more likely to be concerned about how to pay for clinical trial participation.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jeffrey M Weber, MD 2901 W. Kk River Pkwy., Suite 414, Milwaukee, WI 53215-3660 Ph: (414) 649-3750 | Dr Jeffrey M Weber, MD 2901 W. Kk River Pkwy., Suite 414, Milwaukee, WI 53215-3660 Ph: (414) 649-3750 |
News Archive
Tantalizing treasures of neural knowledge that lie deep in the brain of the common fruit fly are one step closer to being laid bare, now that a team of six Stanford researchers has been awarded a $1.3 million medical research grant by the W. M. Keck Foundation.
Nearly two million babies are stillborn every year, with 84 per cent of cases occurring in low- and lower middle-income countries, says an 8 October report by WHO, UNICEF and partners.
Sermo, the world's largest online community for physicians, today announced a Sermo Event Report titled "Is there any Threat to Anti-TNFs from Newer Biologic DMARDs?" In the past year, the FDA has approved four new biologic DMARDs – Actemra (Genentech), Orencia (Bristol-Myers Squibb), Simponi (Centocor Ortho Biotech), and Cimzia (UCB). According to the report, Orencia leads the pack among physicians as the next line of treatment for patients who fail two or more TNF antagonists.
Confluent Surgical, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the DuraSeal Dural Sealant System as the first and only product indicated as an adjunct to sutured dural repair during cranial surgery to achieve watertight closure. The FDA has approved the DuraSeal Sealant with a condition to conduct a post-approval study.
Cancer patients with annual household incomes below $50,000 were less likely to participate in clinical trials than patients with annual incomes of $50,000 or higher, and were more likely to be concerned about how to pay for clinical trial participation.
› Verified 3 days ago
Julia Bonner, M.D. Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 3351 North Downer Avenue, Milwaukee, WI 53211 Phone: 414-229-5684 | |
Dr. Zachary Smith, DO Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 9200 W Wisconsin Ave, Milwaukee, WI 53226 Phone: 414-955-6830 Fax: 414-955-6214 | |
Dr. Christopher Patrick Boyd, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 9200 W Wisconsin Ave, Milwaukee, WI 53226 Phone: 414-805-6000 Fax: 414-805-6280 | |
Umair Bajwa, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 9200 W Wisconsin Ave, Milwaukee, WI 53226 Phone: 414-805-0812 Fax: 414-805-0855 | |
Rasika Surajyam Chepuri, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 9200 W Wisconsin Ave, Milwaukee, WI 53226 Phone: 414-955-7040 Fax: 414-955-6211 | |
Soryal A Soryal, M.D Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1020 N 12th St, 3rd Floor, Milwaukee, WI 53233 Phone: 414-219-7300 | |
Aboud Affi, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1218 W Kilbourn Ave, Suite 404, Milwaukee, WI 53233 Phone: 414-291-3100 |